Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C9 Kits (22) and CYP2C9 Proteins (4) and many more products for this protein.
Showing 10 out of 58 products:
Human Polyclonal CYP2C9 Primary Antibody for Func, IHC (fro) - ABIN2473172
Gilhodes, Gurfinkel, Roll: Role of Ia muscle spindle afferents in post-contraction and post-vibration motor effect genesis. in Neuroscience letters 1992
Show all 4 Pubmed References
Human Monoclonal CYP2C9 Primary Antibody for WB - ABIN1882233
Yang, Cui, Hasi, Jia, Gong, Su: Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. in Genetics and molecular research : GMR 2010
Show all 3 Pubmed References
CYP2C9*2 and CYP2C9*3 genetic polymorphisms are associated with reduced S-warfarin oral clearance in healthy subjects
Case Report: time course of CYP2C9 deinduction appeared to be delayed compared to CYP3A after discontinuation of rifampicin therapy.
Data suggest that SNPs in CYP2C9 (*3, I359L; *30, A477T) that reduce catalytic activity of CYP2C9 also alter interaction with antihypertensive drug losartan; I359L substitution located far from active site remarkably alters residue side chains near active site and access channel, whereas the T477 substitution illustrates hydrogen-bonding interaction with reoriented side chain of Q214.
SNP rs4918758 of CYP2C9 showed a suggestive association with decreased risk of coronary heart disease.
CYP2C9*31075AC genotype with combined alcohol and nevirapine usage indicated a risk for development of antiretroviral-associated hepatotoxicity
CYP2C9 polymorphisms showed no effect on PC doses. Similar findings were observed in the initiation phase of PC therapy. High complications rates under PC therapy were observed particularly at the beginning.
Genetic variants of CYP2C9/VKORC1 (show VKORC1 Antibodies) and age are significant determinants of the maintenance dose of warfarin in patients with atrial fibrillation/valve replacement.
CYP2C9*3 polymorphism genotype and allele frequency were not statistically different between the case and control Ankylosing Spondylitis groups (P>0.05). the efficacy of NSAID in treatment of AS and COX-2 (show COX2 Antibodies) gene -1290A/G and -1195G/A polymorphism were associated (all P<0.05), but it is not associated with CYP2C9 *3 polymorphism (all P>0.05).
polymorphisms c.98T>C in the UGT1A9 (show UGT1A9 Antibodies) and c.1075A>C in the CYP2C9 genes did not affect the pharmacokinetic profile of propofol
Possession of CYP2C9*2 and/or CYP2C9*3 allele variants is associated with lower time of international normalized ratio (INR (show INSR Antibodies)) in the therapeutic range (TTR (show TTR Antibodies)) values and warfarin dose variations in aortic valve replacement patients, the latter affected also by VKORC1 (show VKORC1 Antibodies) c.-1693G>A polymorphism
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P-450 S-mephenytoin 4-hydroxylase
, cytochrome P-450MP
, cytochrome P450 2C9
, cytochrome P450 PB-1
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase